Press release
Navinci Diagnostics AB, a Swedish life science company developing innovative tools for spatial proteomics research, announces the appointment of Dr Subham Basu as new Chief Business Officer, effective April 11th 2023.
Dr Subham Basu will join Navinci to lead the organizational build-up and international commercialization of the unique Navinci product portfolio for Spatial Proteomics, enabling detection of protein-protein interactions in tissue and cell samples.
Prior to joining Navinci, Dr. Basu served as the Senior Director for Commercial Strategy for Immuno-oncology and Oncology at Abcam. He has also worked in medical affairs and market access at AZ, Shire/Baxalta, Otsuka Pharmaceuticals, and Genzyme, where he focused on oncology, hematology, and rare diseases. Additionally, Dr. Basu has served as Head of Strategy at Inflection Point Biomedical Advisors, where he advised the pharmaceutical and diagnostic industries as well as venture capital funds. Before his industry roles, Dr. Basu directed a cancer research laboratory focused on cell signaling and cell biology at Barts Cancer Institute in London.
Subham Basu holds a PhD in Molecular Pharmacology from Cornell’s Weill Graduate School of Medical Sciences (Memorial Sloan Kettering Cancer Center) and a BA in Neuroscience from the University of California at Berkeley.
Navinci offers development services and ready-to-use laboratory reagent kit for the studies of protein-protein interactions and precise protein detections in tissue and cell samples. As previously communicated, the company has launched the first commercial assay to accurately detect and visualize the immune checkpoint interaction between the programmed cell death protein 1 (PD1) and PD1-ligand (PD-L1) in tissue samples. The assay launch is the first step in building a complete portfolio of target-specific assays for immune-oncology research and represents a significant advance in spatial proteomics. Furthermore, Navinci will present four scientific posters at American Association of Cancer Research in Orlando, Florida, this April, highlighting the recent advances in the field.
“I am very excited to join Navinci and contribute to the advances in Spatial Biology Research and Diagnostics. The unique solutions offered by Navinci can significantly contribute to a better understanding of disease mechanisms and will advance drug discovery and translational research in oncology and beyond The great product portfolio and the ambitious team and plans attracted me to the company, and I look much forward to getting onboard and helping researchers across industry and academia.” – Dr Subham Basu, Chief Business Officer
“I am are thrilled to continue the strengthening of the Navinci leadership and welcome Dr Subham Basu to the team. I look much forward to working with him to achieve our goals and drive success for our customers. With his extensive experience and credentials, we know that Subham is well-positioned to help drive the growth of Navinci and further advance our mission of bringing precision to spatial proteomics.” – Robert Gunnarsson, CEO of Navinci Diagnostics AB.